Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410928 | 0.86 | PDE5A (0.51) | — | |
| SCHEMBL5377740 | 0.86 | PDE5A (0.41) | — | |
| SCHEMBL5360622 | 0.83 | MAPK13 (0.39) | — | |
| SCHEMBL6103493 | 0.78 | PDE5A (0.39) | — | |
| SCHEMBL5361647 | 0.78 | PDE5A (0.43) | — | |
| SCHEMBL5355823 | 0.78 | PDE5A (0.41) | — | |
| SCHEMBL5371349 | 0.78 | MTOR (0.40) | — | |
| SCHEMBL5369656 | 0.78 | PDE5A (0.38) | — | |
| SCHEMBL5333399 | 0.75 | PDE5A (0.41) | — | |
| Hydrochloric Acid SCHEMBL5372075 | 0.74 | PDE5A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814885-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006073610-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | HPSE, ENGASE, UGCG | PTGS2 334/4885PTGS1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.